Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Insilico Medicine Doses First Patient in MEN2501 Phase I, Triggers $5M Menarini Milestone

Fineline Cube Feb 3, 2026
Company Deals

PrimeGenX Therapeutics Files Hong Kong IPO for Pumecitinib Platform

Fineline Cube Feb 3, 2026
Company Deals

Jumpcan Licenses PrimeGenX Pumecitinib Nasal Spray for Allergic Rhinitis

Fineline Cube Feb 3, 2026
Company Deals

Arctic Vision-Mdco Technology Merger Builds Ophthalmology Platform

Fineline Cube Feb 3, 2026
Company Deals

SanegeneBio Partners with Genentech on RNAi Therapy in $1.7B Deal

Fineline Cube Feb 3, 2026
Policy / Regulatory

NMPA Releases 101st Batch of Generic Reference Drugs

Fineline Cube Feb 2, 2026
Company Drug

Venglustat Gaucher: Sanofi Meets Primary Endpoint in Phase 3 LEAP2MONO Study

Fineline Cube Feb 3, 2026
Company Drug

Eli Lilly Mounjaro Fails to Win EU Approval for HFpEF Heart Failure Indication

Fineline Cube Feb 3, 2026
Company Drug

Bio-Thera Solutions’ BAT2506 Biosimilar Accepted for Review by China’s NMPA

Fineline Cube Mar 14, 2025

China-based Bio-Thera Solutions Inc. (SHA: 688177) announced that a market filing for its BAT2506, a...

Company Drug

Otsuka and Lundbeck Win EU Approval for Rxulti in Adolescent Schizophrenia

Fineline Cube Mar 14, 2025

Japan-based Otsuka Pharmaceutical Co., Ltd and its Danish partner Lundbeck A/S (OTCMKTS: HLUBF) jointly announced...

Company Drug

Shanghai Fosun Pharmaceutical Gains NMPA Approval for XH-S003 in PNH Treatment

Fineline Cube Mar 14, 2025

China-based Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) announced receiving clinical trial...

Company Drug

Trinomab Biotech Launches Xintituo for Tetanus Treatment in Zhuhai

Fineline Cube Mar 14, 2025

China-based Trinomab Biotech Co., Ltd announced the first delivery of its antitetanus toxin monoclonal antibody...

Company Drug

Tasly Pharma’s NR-20201 Receives NMPA Approval for Acute Ischemic Stroke Trial

Fineline Cube Mar 14, 2025

China-based Tasly Pharma Co., Ltd (SHA: 600535) announced receiving approval from the National Medical Products...

Company Drug

Jiangsu Aidea’s AD108 Receives NMPA Approval for Acute Ischemic Stroke

Fineline Cube Mar 14, 2025

China’s Jiangsu Aidea Pharmaceutical Co., Ltd (SHA: 688488) announced receiving clinical approval from the National...

Company Deals

Insilico Medicine Closes USD110 Million Series E Round to Advance AI-Driven Drug Pipeline

Fineline Cube Mar 14, 2025

China’s generative artificial intelligence (AI)-driven biotech Insilico Medicine announced the completion of a USD110 million...

Company Deals

Sanyou Medical Raises RMB214 Million for Stake in SMTP Technology

Fineline Cube Mar 14, 2025

China-based Shanghai Sanyou Medical Co., Ltd (SHA: 688085) announced the completion of a private placement...

Company Medical Device

Gaush Meditech Receives NMPA Approval for Femtosecond Laser Corneal Refractive Surgery System

Fineline Cube Mar 14, 2025

Suzhou-based Gaush Meditech Ltd (HKG: 2407) announced receiving market approval from the National Medical Products...

Company

Ipsen Appoints Olivia Brown as Global Head of Neurotoxins, Effective April 1st

Fineline Cube Mar 14, 2025

France-based pharmaceutical company Ipsen S.A. (EPA: IPN, OTCMKTS: IPSEY) announced the appointment of Olivia Brown...

Company Drug

China Medical System’s CMS-D003 Receives NMPA Approval for Clinical Study in oHCM

Fineline Cube Mar 14, 2025

China Medical System Holdings (CMS; HKG: 0867) announced receiving approval from the National Medical Products...

Company Drug

Zai Lab Submits TIVDAK BLA to China’s NMPA for Cervical Cancer Treatment

Fineline Cube Mar 14, 2025

Zai Lab Limited (NASDAQ: ZLAB, HKG: 9688) announced that a Biological License Application (BLA) for...

Company Drug

Haisco Pharmaceutical’s HSK44459 Receives NMPA Approval for Psoriasis and Atopic Dermatitis Trials

Fineline Cube Mar 14, 2025

China-based Haisco Pharmaceutical Group Co., Ltd (SHE: 002653) announced receiving approval from the National Medical...

Company Medical Device

Johnson & Johnson MedTech Gains FDA Clearance for MONARCH QUEST with AI Algorithms

Fineline Cube Mar 14, 2025

US major Johnson & Johnson MedTech announced receiving U.S. 510(k) regulatory clearance for its MONARCH...

Company Drug

Arvinas and Pfizer Announce Positive Phase III Results for Vepdegestrant in ER+/HER2- Breast Cancer

Fineline Cube Mar 14, 2025

Partners Arvinas, Inc. (NASDAQ: ARVN) and Pfizer Inc. (NYSE: PFE) announced positive topline results from...

Company

Harbour BioMed Launches Élancé Therapeutics to Tackle Obesity Treatment Challenges

Fineline Cube Mar 14, 2025

China-based Harbour BioMed (HKG: 2142) announced the establishment of Élancé Therapeutics, a new subsidiary focused...

Company Deals

Pierre Fabre Partners with RedRidge Bio on BPA Drug Development for Oncology and Dermatology

Fineline Cube Mar 14, 2025

France-based Pierre Fabre Laboratories announced an exclusive R&D collaboration and license agreement with Switzerland-headquartered RedRidge...

Company Deals

Visen Pharmaceuticals IPO Launches on Hong Kong Stock Exchange Amid Growth in Endocrine Therapies

Fineline Cube Mar 14, 2025

China-based Visen Pharmaceuticals, a joint venture between Denmark-headquartered Ascendis Pharma and Vivo Capital, has successfully...

Company Deals

Roche and Zealand Pharma Collaborate to Develop Petrelintide for Weight Management

Fineline Cube Mar 14, 2025

Swiss pharmaceutical giant Roche (SWX: ROG, OTCMKTS: RHHBY) announced a strategic exclusive collaboration and licensing...

Policy / Regulatory

China Issues Guidelines for Informatization of Compact County-level Medical Communities

Fineline Cube Mar 14, 2025

The National Health Commission (NHC), National Administration of Traditional Chinese Medicine, and National Disease Control...

Posts pagination

1 … 149 150 151 … 618

Recent updates

  • Insilico Medicine Doses First Patient in MEN2501 Phase I, Triggers $5M Menarini Milestone
  • PrimeGenX Therapeutics Files Hong Kong IPO for Pumecitinib Platform
  • Hengrui Resubmits Camrelizumab-Apatinib BLA for HCC to FDA
  • Jumpcan Licenses PrimeGenX Pumecitinib Nasal Spray for Allergic Rhinitis
  • ZEISS ARTEVO Gets NMPA Approval for China Ophthalmology Market
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Insilico Medicine Doses First Patient in MEN2501 Phase I, Triggers $5M Menarini Milestone

Company Deals

PrimeGenX Therapeutics Files Hong Kong IPO for Pumecitinib Platform

Company Medical Device

Hengrui Resubmits Camrelizumab-Apatinib BLA for HCC to FDA

Company Deals

Jumpcan Licenses PrimeGenX Pumecitinib Nasal Spray for Allergic Rhinitis

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.